Adjuvant T-DXd Cuts Recurrence Risk in Early Breast Cancer

(MedPage Today) — Adjuvant trastuzumab deruxtecan (T-DXd; Enhertu) significantly improved invasive disease-free survival compared with trastuzumab emtansine (T-DM1; Kadcyla) in high-risk HER2-positive early breast cancer, according to results…

Source link : https://www.medpagetoday.com/meetingcoverage/esmovideopearls/118303

Author :

Publish date : 2025-11-04 17:07:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Adjuvant T-DXd Cuts Recurrence Risk in Early Breast Cancer

Polycystic ovary syndrome: We’re closing in on how genetics causes PCOS

The fascinating story of the ultimate cosmic law

Related Posts

U.S. Health Spending Topped $5 Trillion in 2024, CMS Says

CDC Just Downgraded Several Vaccines for Kids: Here Are the Risks

CDC’s Reversal on Flu Shots for Kids Could Amplify Outbreaks

Autoimmune Anemia Is the Latest Condition Found Responsive to CAR-T Therapy

GLP-1 Drugs Tied to Mortality Reduction in Colon Cancer Patients With Obesity

FDA Approves At-Home Device for Treatment-Resistant Depression

U.S. Health Spending Topped $5 Trillion in 2024, CMS Says

CDC Just Downgraded Several Vaccines for Kids: Here Are the Risks

CDC’s Reversal on Flu Shots for Kids Could Amplify Outbreaks

Autoimmune Anemia Is the Latest Condition Found Responsive to CAR-T Therapy

GLP-1 Drugs Tied to Mortality Reduction in Colon Cancer Patients With Obesity

FDA Approves At-Home Device for Treatment-Resistant Depression

FDA Calls for New Warning on Flu Shots

Exercise vs Meds for Depression; Supplement’s Suicide Risk; Grants Terminated

Categories

Archives